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INTRODUCTION
Focal segmental glomerulosclerosis (FSGS) is a glo-
merulopathy primarily caused by podocyte injury 
that leads to focal adhesions formation between the 
glomerular tut  and the visceral layer of Bowman cap-
sule (1,2). h e global incidence of FSGS has been esti-
mated at 8 cases/million/year, with 40-60% of patients 
developing end-stage renal disease (ESRD) within 10 
to 20 years at er diagnosis (3,4). Nowadays, i ve forms 
of FSGS have been recognized – genetic, arising from 
multiple nuclear or mitochondrial gene mutations; 
adaptive, associated with disequilibrium in physiolog-
ical load and glomerular i ltration surface; virus-asso-
ciated; drug-induced; and primary (idiopathic)(5). 
Although kidney transplantation (KTx) is the treat-
ment of choice in this specii c group of patients, post-
transplant recurrence of FSGS remains an obstacle 
towards satisfactory long-term allograt  survival (1). 
FSGS recurs in 20-50% of kidney allograt s, with ei-
ther early or late occurence (1,6). Most importantly, 
only primary FSGS recurs following KTx, supporting 
the hypothesis of preexisting immune abnormalities 
which trigger podocyte injury. h ere are numerous 
factors associated with an increased risk of recurrence, 
most of all young age at onset (children < 6 years), se-
vere proteinuria with rapid progression towards ESRD 
in native kidneys, and prior history of allograt  loss 
due to recurrence (7). It is also worth mentioning that 
compared to recurrence of other glomerulopathies, 
patients with FSGS recurrence demonstrate two-fold 
higher risk of losing the allograt  in a 10-year period 
(8).
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h e management of FSGS recurrence is challeng-
ing and unclear, as there are still no well established 
treatment protocols. h us the treatment is mostly 
„empirical“, with therapeutic plasma exchange (TPE) 
and high-dose cyclosporine (CSA) being the corner-
stones of therapy (9). Recent studies have reported an-
ti-CD20 chimeric monoclonal antibody (Rituximab, 
RTX) to be highly ef ective in treating and preventing 
the FSGS recurrence, but further ef orts are needed to 
precisely establish its safety/ei  cacy proi le (9-11).
h e main aim of this study was to evaluate the outcomes 
of kidney transplantation in patients with FSGS treated 
at our Center and discuss available management op-
tions for improved outcomes in this group of patients.
PATIENTS AND METHODS
h e study was carried out at the Department of ne-
phrology, arterial hypertension, dialysis and trans-
plantation, University Hospital Center (UHC) Zagreb. 
All patients with histological evidence of FSGS on a 
native kidney biopsy transplanted during the period 
between October 2007 and October 2013 were ana-
lyzed in this retrospective observational study.
Clinical and laboratory data were obtained from the 
medical records and charts. Data included dialysis 
modality and vintage, comorbidities, type of immu-
nosuppressive regimen, complications at er KTx, 
immunological compatibility and laboratory values 
indicating kidney allograt  function and possible 
FSGS recurrence. h eapeutic plasma exchange was 
performed on Diapact, B.Braun, with exchange of one 
plasma volume, and 5% human albumins as replace-
ment l uid. 
Statistical evaluation of the data was carried out using 
SPSS statistical package, version 17.0 for Windows. 
Baseline data were reported using descriptive statis-
tics. To compare characteristics of two groups Χ2 test 
and t-test were performed, with statistical signii cance 
dei ned as P < 0.05.
RESULTS
Patients’ characteristics
From October 2007 to October 2013, 786 renal trans-
plantations were performed at our institution. A total 
of 30 cases of biopsy-proven FSGS were indentii ed 
during the observed period. Among them, 29 had a 
non-collapsing form of FSGS (ncFSGS), while one 
had collapsing FSGS (cFSGS). h ere were 20 female 
(66.7%) and 10 male (33.3%) patients of mean age 
44.74 ± 4.24 years. h e mean time spent on dialysis 
prior to kidney transplantation was 4.03 ± 0.7 years. 
Comorbidities included predominantly cardiovascu-
lar (n=8) and rheumatoid deseases (n=4). Two patients 
had concomitant hepatitis infection (HBV n=1; HCV 
n=1), and 8 patients showed no signs of comorbidities. 
Deceased donor kidney allograt  received 96.7% of pa-
tients, while one patient was transplanted preemptive-
ly from a living-related donor. Two patients received 
second KTx, their i rst allograt s lost due to FSGS re-
currency. Immunological compatibility was favorable. 
All patients received basiliximab induction, followed 
by the standard immunosuppressive regimen com-
posed of calcineurine inhibitor, mycophenolic acid 
and corticosteroids. Demographic data are summa-
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CSA – cyclosporine A; TAC – tacrolimus; MPA – mycophenolic acid
Patient and gra  survival
Overall patient survival was 90% during the follow-up 
period. Two patients died from infectuous complica-
tions and one at er the acute myocardial infarction.
Eighty percent of patients have satisfactory allograt  
function, with median allograt  survival of 49.15 
months (range 0.5-84 months). Delayed allograt 
function (DGF) occured in 4 cases, but without nega-
tive impact on the long-term allograt  survival. 
Posttransplant complications and FSGS recurrence
One allograt  was lost in the early posttransplant peri-
od due to severe surgical complication (rupture of ex-
ternal illiac artery) demanding prompt artery ligation 
and graphtectomy. Acute rejection episode was record-
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ed in 8 patients – acute cellular rejection (ACR; n=7) 
was successfuly treated with high-dose corticosteroid 
therapy. One patient presented with combined acute 
cellular and humoral rejection diagnosed at er a kid-
ney biopsy performed due to development of nephrotic 
range proteinuria. Combined therapy with corticoste-
roid boluses and TPE was applied, with proteinuria re-
duction and signii cant improvement in grat  function. 
However, three months later proteinuria reapeared 
and the second biopsy, showing no signs of rejection, 
pointed towards something else – cFSGS. TPE was 
commenced once more, followed by RTX therapy, but 
the grat  function rapidly declined and i nally failed.
h e incidence of recurrence was 20% (6/30), with 3 
allograt s lost rapidly due to cFSGS. h e most sud-
den onset of heavy proteinuria was recorded on day 5 
posttransplant, in a young patient with previously di-
agnosed cFSGS on the native kidney biopsy (Fig. 1). 
TPE was initiated but without improvement. 3 patients 
with ncFSGS recurrence have stabile allograt  func-
tion, two of them are treated regularly with TPE. h ere 
was no signii cant dif erence in age, gender distribu-
tion, number or severity of comorbidities, dialysis mo-
dality, DGF and immunological matching between the 
groups wi th the recurrence of either ncFSGS or cFSGS. 
All patients with FSGS recurrence received deceased 
donor allograt . In comparison to cFSGS group, pa-
tients with ncFSGS had longer dialysis duration prior 
to KTx (46±12.28 months vs. 5±1.73 months). cFSGS 
group had higher urine protein excretion (16.37±20.46 
g/dU vs. 4.06±3.84 g/dU; P < 0.001) earlier in the post-
transplant period (1.71 months vs. 10.38 months; P < 
0.05), which resulted with more severe clinical presen-
tation and early allograt  loss (3-6 months posttrans-
plant). As previously mentioned, TPE was successfully 
employed in 2 patients with ncFSGS, while 2 patients 
in the cFSGS group did not respond to intensii ed 
treatment (response rate 50%).
Fig. 1. Pathohistology changes seen in patient with early 
cFSGS recurrence (A and B)
A h e glomerulus shows almost global collapse of the tut , 
with hyperplastic podocytes (PAS stain, magnii cation 200x) 
B h e hyperplastic podocytes contain numerous 
intracytoplasmic, red protein resorption droplets (SFOG 
stain, magnii cation 400x) 
DISCUSSION
FSGS is one of the most common causes of primary 
glomerular disease in adults, its clinical course usu-
ally unpredictable and characterized by the sudden 
onset of nephrotic syndrome followed by the progres-
sion towards ESRD (1-4). h e pathogenesis of FSGS 
is not known, and experimental studies so far support 
the concept of a circulating factor causing podocyte 
foot-process ef acement (12,13). It seems only prima-
ry FSGS recurs following KTx, additionaly supporting 
the hypothesis of preexisting immune abnormalities 
which trigger podocyte injury (8). Because of its high 
occurrence rate at er KTx FSGS remains a challenge 
and a major frustration among nephrologists world-
wide (1,9).
h e main intention of our study was to comprehen-
sively evaluate pretransplant characteristics and out-
comes of patients with FSGS treated at our Center. h e 
results are encouraging with 80% of allograt s showing 
satisfactory function and the overall patient survival of 
90% during the observed period. h e incidence of re-
currence was similar (20%) when compared to previ-
ous studies (6,15-17). Moreover, Francis et al. showed 
even better results when studying the largest FSGS 
cohort by date – only 7.5% of adult population had 
biopsy-proven recurrent FSGS (18). Unfortunatelly, in 
our cohort 3 allograt s were lost rapidly due to cFSGS 
with no response to therapy. 
cFSGS is a distinct histological variant of FSGS charac-
terized by the occurence of heavy nephrotic range pro-
teinuria, progressive deterioration of kidney function 
and quick evolvement towards ESRD (14). It has been 
described in native as well as transplanted kidneys, 
as a recurrent or de novo process, previously linked 
to possible viral (HIV, parvovirus B19, polyomavirus 
species) infection (19,23).Swaminathan and collegues 
demonstrated that cFSGS repesented a more severe 
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form of disease but provided no evidence of viral in-
volment in its pathogenesis (24). Although our study 
is limited by the relatively small size of the cohort (30 
cases) which disabled more thorough statistical anal-
ysis, the sudden and highly agressive nature of cFSGS 
could be clearly seen. cFSGS group had signii cantly 
higher protein excretion early posttransplant, result-
ing in rapid deterioration of allograt  function despite 
prompt diagnosis and targeted treatment. Similar ob-
servations were made in the study of Laurin et al., al-
though at er adjusting for baseline characteristics and 
immunotherapy they showed similar long-term kid-
ney survival between the two FSGS variants (25). We 
did not observe signii cant dif erence in age, gender 
distribution, number or severity of comorbidities, di-
alysis modality, DGF and HLA matching between the 
groups. In comparison to ncFSGS group and patients 
without recurrence, patients with cFSGS had shorter 
dialysis duration prior to KTx which is consistent with 
i ndings of previous reports (26,27).
h e management of FSGS recurrence includes „em-
piricaly“ used combinations of high-dose CSA, RTX 
and TPE aiming the still unindentii ed circulating 
factor (6).TPE has been used frequently since the late 
1980s, at er i rst studies showing benei ts of TPE were 
reported (27,28). Its ei  cacy varies, with the average 
response rate of about 50-60% (15). RTX is not only 
an anti-CD20 monoclonal antibody but also appeares 
to be a regulator of acid sphingomyelinase activity es-
sential for the expression of receptors and signaling 
molecules in podocytes (30). Its benei ts were noted in 
2006 at er complete remission of early recurrent FSGS 
was achieved in a young patient suf ering posttrans-
plantation lymphoproliferative disease (31). In the 
systematic review Araya and Dharnidharka showed 
that remission occured in 64% treated with RTX (10). 
h erapeutic response rate in our cohort was 50%, with 
TPE successfully employed in 2 patients with ncFSGS. 
2 patients in the cFSGS group did not respond to in-
tensii ed treatment (one patient treated with TPE, the 
other treated with the combination on TPE and RTX). 
In this light, it is interesting to discuss the case of a 
young 22-year-old patient (not included in this study), 
with the i rst allograt  lost due to FGSG recurrence. 
Insui  cient vascular access for dialysis brought KTx 
as a „rescue“ therapy, but with a major risk of FSGS 
reocurring once more. We decided to prepare the pa-
tient by doing preemptive PP combined with RTX as 
induction therapy. Regardless of the carefully planned 
protocol, he developed nephrotic range proteinuria 
on day 4 posttransplant. PP were started immediate-
ly, along with the second application of RTX on day 
7. At er the discharge PP had continued twice a week 
for 3 months until proteinuria declined to non-ne-
phrotic range (0.41 g/dU) and remained unchanged 
since. Carefully planned pretransplant therapy led to 
preserving satisfactory allograt  function despite early 
FSGS reocurrence coni rmed by biopsy.
Finally, the importance of early native kidney biopsy 
in all patients with suspected renal disease should be 
emphasized. Glomerulonephritis is the primary cause 
of ESRD in 30-50% of patients receiving kidney al-
lograt . While constant improvement in immunosup-
presive therapy led to decreased number of rejection 
episodes, it did not af ect the ocurrence of recurrent or 
de novo glomerulopathies as the third most common 
cause of allograt  loss during the 10-year period (32-
34). Two patients from our cohort did not have precise 
primary disease diagnosis. One patient was character-
ized as „chronic glomerulonephritis without biopsy“ 
and the second as „nephroangiosclerosis“. Neverthe-
less, they were included in the study. First of all, these 
were young patients who started hemodialysis shortly 
at er presenting abruptly with marked edema and hy-
pertensive crisis. Secondly, they developed nephrotic 
range proteinuria within the 3 months posttransplant, 
with allograt  biopsy showing clear signs of FSGS. One 
patient had nc FSGS variant, positively responsing 
to TPE, while the other was mentioned prevously as 
combined ACR/AHR with cFSGS described at er the 
second biopsy. She lost the allograt  6 months post-
transplant, although prompt TPE combined with 
RTX administration was started. As early recurrence 
is mainly linked to recurrent FSGS, bearing in mind 
severity of clinical presentation and quick progression 
towards ESRD before KTx diagnosis of FSGS as pri-
mary glomerulopathy is most likely. De novo FSGS ap-
pears fairly late, at a mean of 57 months posttransplant 
and proteinuria 2.4 g/dU, and is hard to dif erentiate 
from chronic allograt  nephropathy (35). h us our 
future ef orts should lead towards precise diagnose of 
underlying kidney disease and careful choice of post-
transplant treatment strategy in order to improve and 
optimize allograt  longevity.
CONCLUSION
Although an increased risk of recurrence exists, kid-
ney transplantation remains the treatment of choice 
for patients with FSGS. h orough treatment planning 
should be made before undergoing KTx, with pre-
emptive TPE and RTX induction as possible options. 
Urinary protein excretion should be closely monitored 
on a daily basis in the early posttransplant period and 
then slowly tappered in the i rst transplant year when 
the risk of recurrence is the highest. Immediate al-
lograt  biopsy should be performed in all patients de-
veloping proteinuria and prompt therapy should be 
started. Despite no clear evidence, intensive TPE reg-
imen should be started in every patient, followed by 
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RTX administration in patients showing no response 
to previous treatment attempts. Sometimes prolonged 
treatment is needed before achieving remission.
Further studies are needed in order to precisely dei ne 
FSGS pathophysiology and provide stronger evidence 
of TPE and RTX treatment benei ts.
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Uvod i ciljevi: Povratak fokalne segmentalne glomerularne skleroze (FSGS) u presadak i dalje ostaje važna prepreka 
u postizanju dugoročno zadovoljavajućih rezultata transplantacije bubrega. Glavni cilj istraživanja bio je procijeniti 
ishode bolesnika praćenih u našem Centru te raspraviti nove mogućnosti u liječenju ove skupine bolesnika. Ispitanici i 
metode: U istraživanje su uključeni svi bolesnici (n=30; 33,3 % muškaraca) s dijagnozom FSGS vlastitih bubrega, liječeni 
transplantacijom u razdoblju od listopada 2007. i listopada 2013. Svi istraživani parametri prikupljeni su iz dostupne 
medicinske dokumentacije. Rezultati: 29 bolesnika imalo je nekolabirajuću FSGS (ncFSGS), dok je u jednog bolesnika 
ustanovljena kolabirajuća varijanta bolesti (cFSGS). Kadaverični presadak primilo je 96,7 % bolesnika. Ukupno preživljenje 
bolesnika tijekom praćenja iznosilo je 90 %. Osamdeset posto bolesnika imalo je zadovoljavajuću funkciju presatka uz 
medijan preživljenja 49,15 (0,5-84) mjeseci. Incidencija povratka bolesti u presadak bila je 20 % (6/30), a 3 presatka su 
promptno izgubila svoju funkciju zbog cFSGS. Skupina bolesnika sa cFSGS varijantom izražavala je višu proteinuriju 
značajno ranije u posttransplantacijskom razdoblju (P <0,05), što se u konačnici odrazilo težom kliničkom slikom i ranim 
gubitkom presatka (3-6 mjeseci nakon transplantacije). Terapijskim izmjenama plazme uspješno su liječena dva bolesnika 
s ncFSGS, dok dva bolesnika s cFSGS varijantom nisu odgovorila na terapiju (50 %-tni odgovor na terapiju). Zaključak: 
Iako je rizik za povratak FSGS u presadak visok, transplantacija bubrega i dalje je zlatni standard u liječenju bolesnika s 
FSGS. Neophodno je bez odgađanja učiniti biopsiju presatka u svih bolesnika s razvojem proteinurije kako bi se na vrijeme 
započela specifi čna terapija i poboljšao ishod.
Ključne riječi: fokalna segmentalna glomerularna skleroza; transplantacija bubrega; ishod 
S A Ž E T A K
TRANSPLANTACIJA BUBREGA KOD BOLESNIKA S FOKALNOM SEGMENTALNOM 
GLOMERULOSKLEROZOM
L. KATALINIĆ1, L. GELLINEO1, M. ĆORIĆ2,4 i N. BAŠIĆ-JUKIĆ1,2,3
1Klinički bolnički centar Zagreb, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, 
2Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, 3Sveučilište u Osijeku, Medicinski fakultet, Osijek i 4Klinički 
bolnički centar Zagreb, Zavod za patologiju, Zagreb, Hrvatska
